Quantum BioPharma Ltd. (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (MS). The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026 and moves the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies.
The deal matters because it pairs Quantum’s lead asset with a CRO that has deep experience in MS trials, potentially streamlining the path from regulatory clearance to trial execution. Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. That mechanism represents a different therapeutic strategy for progressive forms of the disease, which have limited treatment options.
The randomized, double-blind, placebo-controlled trial will evaluate the candidate’s safety, tolerability and efficacy using clinical and radiological measures. Although preclinical research and Phase 1 testing have provided encouraging findings, Lucid-MS remains investigational, and the company has not yet announced enrollment dates or trial sites. For a fuller account, see the original article.
Quantum BioPharma describes itself as a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS. More information is available at www.QuantumBioPharma.com, and the latest updates on QNTM are posted in the company’s newsroom at https://ibn.fm/QNTM.
The announcement was distributed through InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire notes that its services include editorial syndication to 5,000+ outlets and social media distribution, among other offerings. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
